Limiting the availability of iron for erythropoiesis through ferroportin inhibition might be a possible treatment approach for patients with β-NTDT, as well as those with other conditions associated with ineffective erythropoiesis or iron overload such as sickle cell disease, polycythemia vera, and hemochromatosis. The gene discussed is SLC40A1; the disease is Tangier disease.